Eflornithine

證據等級: L5

預測適應症: 10 個

Eflornithine: From Human African Trypanosomiasis to Esotropia

One-Sentence Summary

Eflornithine (DFMO, difluoromethylornithine) is an irreversible inhibitor of ornithine decarboxylase (ODC), established as the treatment of choice for late-stage Gambian human African trypanosomiasis (sleeping sickness). The TxGNN model predicts it may be effective for Esotropia (inward deviation of the eye), with no clinical trials and no publications currently available to support this specific direction. This prediction is currently unsupported by direct clinical evidence and should be considered exploratory.

Quick Overview

Item	Content
Original Indication	Human African Trypanosomiasis (late-stage Gambian sleeping sickness)
Predicted New Indication	Esotropia
TxGNN Prediction Score	99.85%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on published literature retrieved for related indications, eflornithine acts as an irreversible, mechanism-based inhibitor of ornithine decarboxylase (ODC) — the rate-limiting enzyme in the polyamine biosynthesis pathway. By permanently blocking ODC, eflornithine depletes intracellular polyamines (putrescine, spermidine, spermine), which are essential regulators of cell proliferation, differentiation, and gene expression. This is the same mechanism underlying its efficacy against Trypanosoma brucei gambiense, which is exquisitely sensitive to polyamine depletion.

Esotropia is a form of strabismus characterised by inward misalignment of one or both eyes, typically arising from imbalanced extraocular muscle tone or neurodevelopmental deficits in ocular motor control. The mechanistic bridge between polyamine pathway inhibition and esotropia is not established in the current literature. TxGNN’s knowledge graph may be identifying indirect network relationships — for instance, shared molecular nodes involved in neuronal development, axonal guidance, or neuromuscular junction remodelling — but no direct pharmacological evidence currently supports this link.

It is worth noting that eflornithine’s best-evidenced predicted indications in this pack involve haematological and parasitic contexts (monoclonal gammopathy: 9 publications; bovine trypanosomiasis: 2 publications), which align more naturally with its known ODC-inhibitory mechanism. The esotropia prediction, while receiving the highest TxGNN score (99.85%), lacks any supporting clinical or preclinical literature and warrants cautious interpretation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Eflornithine is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No ARTG entries exist for this drug. Any future use in Australia would require a TGA registration pathway (e.g., full registration, or access via the Special Access Scheme or Authorised Prescriber pathway).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No safety data (warnings, contraindications, or drug interactions) was retrieved in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: Eflornithine is not registered in Australia, there is no clinical trial or published literature evidence linking it to esotropia, mechanism of action data is unavailable, and no safety information has been retrieved — the evidence base does not meet the minimum threshold required to proceed.

To proceed, the following is needed:

Mechanism of action confirmation: Obtain full MOA data from DrugBank to determine whether any plausible pharmacological link to esotropia (e.g., neuromuscular or developmental polyamine pathway involvement) can be identified
Preclinical evidence search: Broaden literature search to include animal models or in vitro studies involving eflornithine and ocular or strabismus-related endpoints
Safety data: Download and parse the approved Product Information (PI) from any jurisdiction (e.g., US FDA label, EMA SmPC) to complete warnings, contraindications, and drug interaction profiling
TGA regulatory pathway assessment: Determine the most appropriate access pathway given Australia’s current zero-registration status for this drug
Consider higher-ranked evidence indications: Monoclonal gammopathy (9 publications, ODC/DFMO mechanistic link) and bovine trypanosomiasis (2 publications, direct mechanistic link) may be more productive repurposing candidates to evaluate next, given stronger existing evidence chains

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.